[go: up one dir, main page]

EE200200504A - Pharmaceutical preparations - Google Patents

Pharmaceutical preparations

Info

Publication number
EE200200504A
EE200200504A EEP200200504A EEP200200504A EE200200504A EE 200200504 A EE200200504 A EE 200200504A EE P200200504 A EEP200200504 A EE P200200504A EE P200200504 A EEP200200504 A EE P200200504A EE 200200504 A EE200200504 A EE 200200504A
Authority
EE
Estonia
Prior art keywords
formulations
release
relates
fusion
pharmaceutical formulations
Prior art date
Application number
EEP200200504A
Other languages
Estonian (et)
Inventor
Hoffmann Torsten
Pieroth Michael
Zessin Gerhard
Landgraf Karl-Friedrich
Original Assignee
Awd.Pharma Gmbh & Co. Kg
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=26004678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=EE200200504(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority claimed from DE2000110509 external-priority patent/DE10010509A1/en
Application filed by Awd.Pharma Gmbh & Co. Kg filed Critical Awd.Pharma Gmbh & Co. Kg
Publication of EE200200504A publication Critical patent/EE200200504A/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1682—Processes
    • A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1617—Organic compounds, e.g. phospholipids, fats
    • A61K9/1623—Sugars or sugar alcohols, e.g. lactose; Derivatives thereof; Homeopathic globules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/26—Psychostimulants, e.g. nicotine, cocaine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/10—Antioedematous agents; Diuretics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/06—Antiarrhythmics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Pain & Pain Management (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Obesity (AREA)
  • Hospice & Palliative Care (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Psychiatry (AREA)
  • Psychology (AREA)
  • Immunology (AREA)
  • Anesthesiology (AREA)
  • Endocrinology (AREA)
  • Emergency Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Otolaryngology (AREA)
  • Biophysics (AREA)

Abstract

The invention relates to novel oral pharmaceutical formulations having a variably adjustable release effect . Said formulations contain one or several sucrose fatty acid esters as exclusive release control agents, in addition to one or several active ingredients. The invention also relates to a method for the production of the formulations by fusion granulation or fusion pelletizing . The novel pharmaceutical formulations range from quick release to delayed release medicament forms.
EEP200200504A 2000-03-08 2001-03-06 Pharmaceutical preparations EE200200504A (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DE2000110509 DE10010509A1 (en) 2000-03-08 2000-03-08 Oral pharmaceutical formulations with controllable release characteristics, e.g. rapid or delayed release, contain sucrose fatty acid ester as drug release controlling agent
US18796200P 2000-03-09 2000-03-09
PCT/EP2001/002500 WO2001066081A2 (en) 2000-03-08 2001-03-06 Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients

Publications (1)

Publication Number Publication Date
EE200200504A true EE200200504A (en) 2004-02-16

Family

ID=26004678

Family Applications (1)

Application Number Title Priority Date Filing Date
EEP200200504A EE200200504A (en) 2000-03-08 2001-03-06 Pharmaceutical preparations

Country Status (22)

Country Link
EP (1) EP1267828B1 (en)
JP (1) JP2003528829A (en)
KR (1) KR20020083171A (en)
CN (1) CN1212831C (en)
AT (1) ATE334659T1 (en)
AU (1) AU2001250365A1 (en)
BG (1) BG107064A (en)
BR (1) BR0109036A (en)
CA (1) CA2339913C (en)
CZ (1) CZ20023009A3 (en)
DE (1) DE50110617D1 (en)
EA (1) EA200200951A1 (en)
EE (1) EE200200504A (en)
GE (1) GEP20053455B (en)
HR (1) HRP20020804B1 (en)
HU (1) HUP0204513A3 (en)
IS (1) IS6511A (en)
NO (1) NO20024237D0 (en)
NZ (1) NZ521215A (en)
PL (1) PL202935B1 (en)
SK (1) SK13252002A3 (en)
WO (1) WO2001066081A2 (en)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2005527508A (en) * 2002-03-07 2005-09-15 ヴェクトゥラ　リミテッド Rapid melting multiparticulate formulation for oral delivery
CN100500130C (en) * 2003-01-23 2009-06-17 株式会社太平洋 Sustained-release preparation and preparation method thereof
DE10341264A1 (en) * 2003-09-04 2005-03-24 Grünenthal GmbH Melt-formulated, multiparticulate oral dosage form
KR20060134041A (en) * 2004-04-22 2006-12-27 모르 리서치 애플리케이션즈 리미티드 How to manage food intake
WO2010009433A1 (en) * 2008-07-18 2010-01-21 Valeant Pharmaceuticals International Modified release formulation and methods of use
US8715715B2 (en) * 2008-11-03 2014-05-06 Nal Pharmaceuticals Ltd. Dosage form for insertion into the mouth
DE102009013612A1 (en) 2009-03-17 2010-09-23 Ratiopharm Gmbh Retigabine tablets, preferably with modified release
DE102009013613A1 (en) 2009-03-17 2010-09-23 Ratiopharm Gmbh Dry processing of retigabine
DE102009013611A1 (en) 2009-03-17 2010-09-23 Ratiopharm Gmbh Solid retigabine in non-crystalline form
EA201290663A1 (en) * 2010-01-20 2013-03-29 Вэлиант Фармасьютикалс Интернешнл COMPOSITION WITH MODIFIED SHIPPING AND METHODS OF APPLICATION
WO2013004249A1 (en) 2011-07-05 2013-01-10 Concit Pharma Aps The use of serotonin receptor agonists for treatment of movement disorders
AU2014340710B2 (en) * 2013-10-29 2019-08-22 Echo Pharmaceuticals B.V. Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
AU2017361129B2 (en) * 2016-11-18 2023-11-09 Telethon Kids Institute Taste masking product
CN107441055A (en) * 2017-08-03 2017-12-08 山东则正医药技术有限公司 A kind of preparation method of controlled release drug
CN108853044B (en) * 2018-07-06 2020-11-06 郑州明泽医药科技有限公司 Nifedipine sustained release tablet and preparation method thereof
CN109679147B (en) * 2018-12-28 2021-05-11 广西科技师范学院 Plant microfine fiber sucrose fatty acid ester enrichment and preparation method thereof
GB201904767D0 (en) 2019-04-04 2019-05-22 Orexo Ab New pharmaceutical compositions
WO2021145625A1 (en) * 2020-01-13 2021-07-22 한국유나이티드제약 주식회사 Pharmaceutical composition comprising r-thioctic acid or pharmaceutically acceptable salt thereof and enteric coating base material
CN111513192A (en) * 2020-05-19 2020-08-11 北京中联华康科技有限公司 Esterified cysteamine hydrochloride stable powder and preparation method and application thereof
CN114983964B (en) * 2022-06-24 2024-05-03 广东恒健制药有限公司 Cefdinir granule and preparation method thereof

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS63101320A (en) * 1986-10-17 1988-05-06 Dainippon Pharmaceut Co Ltd Calcium valproate preparation
JPH07267850A (en) * 1994-03-28 1995-10-17 Eisai Co Ltd Medicine composition prevented in unpleasant taste and method for producing the same
JP4078567B2 (en) * 1997-04-25 2008-04-23 東和薬品株式会社 Sustained release microcapsules and production method thereof
JP4299384B2 (en) * 1997-07-15 2009-07-22 富山化学工業株式会社 Anti-elution delay fine granules
AU749623B2 (en) * 1998-03-26 2002-06-27 Astellas Pharma Inc. Sustained release preparations
DE19840152A1 (en) * 1998-09-03 2000-03-09 Dresden Arzneimittel Pharmaceutical compositions containing calcium valproate with a delayed release of active substance, process for their preparation and their use
DE19916383A1 (en) * 1999-03-31 2000-10-05 Schering Ag Pharmaceutical composition with an extrusion

Also Published As

Publication number Publication date
NZ521215A (en) 2005-04-29
CZ20023009A3 (en) 2003-06-18
HK1054697A1 (en) 2003-12-12
CN1418091A (en) 2003-05-14
JP2003528829A (en) 2003-09-30
EP1267828B1 (en) 2006-08-02
DE50110617D1 (en) 2006-09-14
NO20024237L (en) 2002-09-05
HUP0204513A2 (en) 2003-05-28
EA200200951A1 (en) 2003-02-27
NO20024237D0 (en) 2002-09-05
KR20020083171A (en) 2002-11-01
ATE334659T1 (en) 2006-08-15
AU2001250365A1 (en) 2001-09-17
CN1212831C (en) 2005-08-03
CA2339913C (en) 2009-02-24
WO2001066081A2 (en) 2001-09-13
BG107064A (en) 2003-04-30
HRP20020804A2 (en) 2004-12-31
GEP20053455B (en) 2005-02-25
CA2339913A1 (en) 2001-09-08
SK13252002A3 (en) 2003-07-01
PL202935B1 (en) 2009-08-31
PL362547A1 (en) 2004-11-02
BR0109036A (en) 2003-03-18
WO2001066081A3 (en) 2002-03-14
IS6511A (en) 2002-08-20
EP1267828A2 (en) 2003-01-02
HRP20020804B1 (en) 2008-06-30
HUP0204513A3 (en) 2004-06-28

Similar Documents

Publication Publication Date Title
EE200200504A (en) Pharmaceutical preparations
IL158589A (en) Carboxylic acid substituted oxazole derivatives, process for their manufacture, pharmaceutical compositions comprising them and use thereof in the preparation of medicaments for the treatment and prophylaxis of diseases which are modulated by ppar-alpha and -gamma activators
PT1311285E (en) Liquid pharmaceutical composition containing a derivative of erythropoietin
WO2001098290A3 (en) Thiophene derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions comprising them
IL159843A0 (en) Amino-phthalazinone derivatives active as kinase inhibitors, process for their preparation and pharmaceutical compositions containing them
TNSN01108A1 (en) Oxygenated esters of 4-iodo phenylamino benzhydroxamic acids
IL145430A0 (en) N-cyanomethyl amides, processes for the preparation thereof and pharmaceutical compositions containing the same
DE60138468D1 (en) CYANOPHENOXY CARBOXYLIC ACIDS AND COMPOSITIONS FOR THE RELEASE OF ACTIVE SUBSTANCES
WO2001095856A3 (en) Urea derivative useful as an anti-cancer agent and process for preparing same
BRPI0408555A (en) controlled release system
NO20023551D0 (en) Ibuprofen-containing active agent preparation
MXPA02012889A (en) 4-alkoxy cyclohexane-1 amino carboxylic acid esters and method for the production thereof.
WO2005065639A3 (en) Novel pharmaceutical compositions
BR0311642A (en) Increased Release Sodium Divalproex Formulation
DE60131416D1 (en) CHIRAL FLUOROCHINOLICININE ARGININE SALT
PE20040916A1 (en) PYRIMIDIN-4,6-DICARBOXYL ACID DIAMIDES AS SELECTIVE INHIBITORS OF MMP-13
EA200700703A1 (en) GRANULAR PREPARATIONS OF HOBOXADOL
ATE324103T1 (en) CONTROLLED RELEASE MEDICINAL PREPARATION CONTAINING TRAMADOL HYDROCHLORIDE
ATE307809T1 (en) NOVEL PYRIMIDINE DERIVATIVES AND METHOD FOR THEIR PRODUCTION
CA2429793A1 (en) Interferon therapeutic effect enhancer
YU66902A (en) Pharmaceutical preparations containing saccharose fatty acid esters for controlling the release of active ingredients
NO20054417L (en) Process for the preparation of pharmaceutical preparations in the form of fibrate-containing tablets and the tablets thus prepared
WO2007025764A3 (en) Pharmaceutical formulations for salts of monobasic acids comprising clopidogrel
WO2002030391A3 (en) Method for determining the release of a peptide from a sustained release polylactide formulation
AU2001274138A1 (en) Propanolaminotetralines, preparation thereof and compositions containing same